Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy

J Am Soc Nephrol. 2015 Dec;26(12):2963-77. doi: 10.1681/ASN.2014050528. Epub 2015 Apr 8.

Abstract

Expression of thioredoxin-interacting protein (TxNIP), an endogenous inhibitor of the thiol oxidoreductase thioredoxin, is augmented by high glucose (HG) and promotes oxidative stress. We previously reported that TxNIP-deficient mesangial cells showed protection from HG-induced reactive oxygen species, mitogen-activated protein kinase phosphorylation, and collagen expression. Here, we investigated the potential role of TxNIP in the pathogenesis of diabetic nephropathy (DN) in vivo. Wild-type (WT) control, TxNIP(-/-), and TxNIP(+/-) mice were rendered equally diabetic with low-dose streptozotocin. In contrast to effects in WT mice, diabetes did not increase albuminuria, proteinuria, serum cystatin C, or serum creatinine levels in TxNIP(-/-) mice. Whereas morphometric studies of kidneys revealed a thickened glomerular basement membrane and effaced podocytes in the diabetic WT mice, these changes were absent in the diabetic TxNIP(-/-) mice. Immunohistochemical analysis revealed significant increases in the levels of glomerular TGF-β1, collagen IV, and fibrosis only in WT diabetic mice. Additionally, only WT diabetic mice showed significant increases in oxidative stress (nitrotyrosine, urinary 8-hydroxy-2-deoxy-guanosine) and inflammation (IL-1β mRNA, F4/80 immunohistochemistry). Expression levels of Nox4-encoded mRNA and protein increased only in the diabetic WT animals. A significant loss of podocytes, assessed by Wilms' tumor 1 and nephrin staining and urinary nephrin concentration, was found in diabetic WT but not TxNIP(-/-) mice. Furthermore, in cultured human podocytes exposed to HG, TxNIP knockdown with siRNA abolished the increased mitochondrial O2 (-) generation and apoptosis. These data indicate that TxNIP has a critical role in the progression of DN and may be a promising therapeutic target.

Keywords: diabetes mellitus; diabetic nephropathy; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albuminuria / etiology
  • Animals
  • Antigens, Differentiation / analysis
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism*
  • Cells, Cultured
  • Collagen Type IV / analysis
  • Creatinine / blood
  • Cystatin C / blood
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / metabolism*
  • Diabetic Nephropathies / metabolism*
  • Fibrosis
  • Glomerular Basement Membrane / pathology
  • Glucose / pharmacology
  • Interleukin-1beta / genetics
  • Kidney Glomerulus / chemistry
  • Kidney Glomerulus / pathology
  • Membrane Proteins / analysis
  • Mice
  • Mice, Knockout
  • Mitochondria / drug effects
  • Mitochondria / genetics
  • Mitochondria / metabolism
  • NADPH Oxidase 4
  • NADPH Oxidases / genetics
  • NADPH Oxidases / metabolism
  • Oxidative Stress
  • Oxygen / metabolism
  • Podocytes / chemistry
  • Podocytes / drug effects
  • Podocytes / pathology
  • RNA, Messenger / analysis
  • Repressor Proteins / analysis
  • Streptozocin
  • Thioredoxins / genetics
  • Thioredoxins / metabolism*
  • Transforming Growth Factor beta1 / analysis
  • WT1 Proteins

Substances

  • Antigens, Differentiation
  • Carrier Proteins
  • Collagen Type IV
  • Cystatin C
  • Interleukin-1beta
  • Membrane Proteins
  • RNA, Messenger
  • Repressor Proteins
  • Transforming Growth Factor beta1
  • Txnip protein, mouse
  • WT1 Proteins
  • WT1 protein, mouse
  • monocyte-macrophage differentiation antigen
  • nephrin
  • Thioredoxins
  • Streptozocin
  • Creatinine
  • NADPH Oxidase 4
  • NADPH Oxidases
  • Nox4 protein, mouse
  • Glucose
  • Oxygen